Top Markets
Coin of the day
Wuhan YZY Biopharma Co Ltd Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd

2496
Clasificación en acciones #22213
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the... Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Precio por acción
$0.46053443
Última sincronización: 2026-08-13
Capitalización bursátil
$92.44M
Cambio (1 día)
0.00%
Cambio (1 año)
-36.86%
País
CN
Comercio Wuhan YZY Biopharma Co Ltd (2496)

Categoría

Ganancias de Wuhan YZY Biopharma Co Ltd (2496)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Wuhan YZY Biopharma Co Ltd, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Wuhan YZY Biopharma Co Ltd desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH